CRISPR Therapeutics
CRSP
404 hedge funds and large institutions have $2.54B invested in CRISPR Therapeutics in 2024 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 114 increasing their positions, 122 reducing their positions, and 70 closing their positions.
5.29% more ownership
Funds ownership: 70.34% → 75.64% (+5.3%)
6% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 70
7% less repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 122
3% less funds holding
Funds holding: 416 → 404 (-12)
10% less capital invested
Capital invested by funds: $2.81B → $2.54B (-$271M)
11% less call options, than puts
Call options by funds: $81.6M | Put options by funds: $91.6M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$69.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$69.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$61.9M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$50.7M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$38.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$28.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$23.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$21M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$17.1M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$10.5M |
CRSP Hedge Fund Activity: Q4 2024 in Review
404 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2024, worth a combined $2.54B — down 9.6% from $2.81B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of CRSP and 66 opened new positions — a net loss of 4 holders — while 122 trimmed existing stakes and 114 added.
The largest buyer was Orbis Allan Gray, opening a new position worth an estimated $69.7M. The largest seller was Bellevue Group, exiting entirely with an estimated $28.7M sold.
- 404 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2024, down from 416 in Q3 2024.
- Funds reported $2.54B of CRISPR Therapeutics stock for Q4 2024, down 9.6% quarter-over-quarter.
- 66 funds opened new CRISPR Therapeutics positions in Q4 2024 and 70 closed out, a net change of -4 holders.
- The largest CRISPR Therapeutics buyer in Q4 2024 was Orbis Allan Gray, an estimated $69.7M added.
- The largest CRISPR Therapeutics seller in Q4 2024 was Bellevue Group, an estimated $28.7M sold.
Based on aggregated 13F filings for Q4 2024.